ATENT COOPERATION TREATY





INTERNATIONAL PRELIMINARY EXAMINATION REPORT

anslation internation	ATENT COOPER	ATION TRE	ATY OpenMARS
ansile internati	ONAL PRELIMINA	_	ATION REPORT
	(PCT Article 3	6 and Rule 70)	
Applicant's or agent's file reference PH-1875-PCT	FOR FURTHER ACT	ION See Notific	cation of Transmittal of Internations Examination Report (Form PCT/IPEA/416
International application No. PCT/JP2003/011318	International filing date 04 September 200		Priority date (day/month/year) 04 September 2002 (04.09.2002)
International Patent Classification (IPC) or C12N 15/06, C07K 16/18	national classification and	IPC	
Applicant CH	IUGAI SEIYAKU KA	ABUSHIKI KAI	SHA
amended and are the basis: 70.16 and Section 607 of th These annexes consist of a 3. This report contains indications re I Basis of the report II Priority III Non-establishment IV Lack of unity of i	nied by ANNEXES, i.e., s for this report and/or sheets the Administrative Instruction total ofs clating to the following item t t of opinion with regard to	neets of the descript containing rectific ons under the PCT). neets.	ion, claims and/or drawings which have be ations made before this Authority (see Ru
VI Certain document	anations supporting such s	on	inventive step or industrial applicability;
Date of submission of the demand		Date of completion	n of this report
04 September 2003 (0	4.09.2003)	23	February 2004 (23.02.2004)
Name and mailing address of the IPEA/J	TP	Authorized officer	
Facsimile No.		Telephone No.	



Internation application No.

PCT/JP2003/011318


I. Bas	is of the ı	report		
1. Wi	th regard	to the elements of the international application:*	1	
\boxtimes	the in	nternational application as originally filed		
	the de	escription:		
	- pages		, as originally filed	
	pages		led with the demand	
	pages	s, filed with the letter of		
	the cl	laims:		
	_ pages		_, as originally filed	
	pages	s , as amended (together with any statem	ent under Article 19	
	pages	. г.	lied with the demand	
l	pages			
Г	the d	drawings:		
<u>. </u>	→ page:	es	_ , as originally filed	
	page	.,1	ned with the demand	
	page			
Г	T the sea	quence listing part of the description:	·	
╎└╴	page	•	_ , as originally filed	
1	page		iled with the demand	
	page			
2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language which is the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).				
		language of publication of the international application (under Rule 48.3(b)).	under Rule 55.2 and/	
L	or 5	language of the translation furnished for the purposes of international preliminary examination (55.3).		
3. \	With rega reliminar	ard to any nucleotide and/or amino acid sequence disclosed in the international applicati ry examination was carried out on the basis of the sequence listing:	on, the international	
إ	=	ntained in the international application in written form.		
֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓		ed together with the international application in computer readable form.		
		nished subsequently to this Authority in written form.		
		nished subsequently to this Authority in computer readable form.	1 1 1 1 in the	
	inte	e statement that the subsequently furnished written sequence listing does not go beyond ternational application as filed has been furnished.		
		e statement that the information recorded in computer readable form is identical to the written en furnished.	sequence listing has	
4.	The	ne amendments have resulted in the cancellation of:		
		the description, pages		
1		the claims, Nos		
		the drawings, sheets/fig		
5.	Thi bey	is report has been established as if (some of) the amendments had not been made, since they have youd the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**	been considered to go	
1 /	Replacem in this re and 70.17	nent sheets which have been furnished to the receiving Office in response to an invitation under Art eport as "originally filed" and are not annexed to this report since they do not contain am 7).	ticle 14 are referred to endments (Rule 70.16	
		coment sheet containing such amendments must be referred to under item 1 and annexed to this rep	ort.	

INTERNATIONAL PRELIM ARY EXAMINATION REPORT

Internation pplication No.	
Г/ЈР03/11318	

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:					
th.	e entire international application.				
Cl:	aims Nos				
because:					
⊠ th	le said international application, or the said claims Nos				
and PCT R	The above claims encompass diagnostic methods for the human body to which PCT Article 34(4)(a)(i) and PCT Rule 67.1(iv) apply, which do not require an international preliminary examination by the International Preliminary Examining Authority.				
ti a	he description, claims or drawings (<i>indicate particular elements below</i>) or said claims Nosre so unclear that no meaningful opinion could be formed (<i>specify</i>):				
	the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.				
	no international search report has been established for said claims Nos				
2. A meani	ingful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid the listing to comply with the standard provided for in Annex C of the Administrative Instructions:				
_	the written form has not been furnished or does not comply with the standard.				
	the computer readable form has not been furnished or does not comply with the standard.				

INTERNATIONAL PRELIMENT RY EXAMINATION REPORT



v.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

tement			
Novelty (N)	Claims	14-16	YE
	Claims	1-13	NO
Inventive step (IS)	Claims	14-16	YE
	Claims	1-13	NO
Industrial applicability (IA)	Claims	1-16	YE
	Claims		NO

2. Citations and explanations


Document 1: Proceedings of the American Association for Cancer Research Annual Meeting, March 2002, Vol. 43, page 219

The subject matters of claims 1-13 do not appear to be novel or to involve an inventive step because they are described document 1 cited in the ISR. Document 1 describes an anti-GPC3 mouse monoclonal antibody.

Document 1 does not describe that the above-mentioned antibody is used as a cell-disrupting agent and an anticancer agent, and so the subject matters of claims 14-16 would not be obvious to a person skilled in the art.

INTERNATIONAL PRELING

ARY EXAMINATION REPORT



VI. Certain documents cited

Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
W0 03/000883 A1	03.01.2003	21.06.2002	22.06.2001
[E, X] W0 03/010336 A2 [E, X]	06.02.2003	25.07.2002	25.07.2001

2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure

Date of non-written disclosure (day/month/year)

Date of written disclosure referring to non-written disclosure (day/month/year)